Bernd Brust is the Chief Executive Officer of Maravai LifeSciences Holdings, Inc., a global leader in providing high-quality life sciences reagents and services essential for mRNA therapeutics, vaccines, and genomic research. With more than 25 years of executive experience in diagnostics, genomics, and biotechnology, Brust has a proven track record of scaling innovative businesses and driving commercial success in highly regulated industries. He assumed the CEO role at Maravai in October 2021, steering the company through rapid growth amid the surge in demand for mRNA technologies. Prior to Maravai, Brust served as President of the Diagnostics and Genomics Group at Agilent Technologies, where he led a $2.5 billion business unit, expanding its portfolio in next-generation sequencing, PCR, and companion diagnostics to advance precision medicine. Earlier, he held senior leadership roles at Roche Diagnostics for over a decade, culminating as President and Head of Roche Professional Diagnostics. In this position, he oversaw global operations across more than 100 countries, launching groundbreaking products that captured significant market share and generated billions in revenue. Under Brust's leadership, Maravai has achieved remarkable milestones, including scaling production of its proprietary CleanCap mRNA capping technology to support major COVID-19 vaccine programs and completing strategic acquisitions to bolster its synthetic biology offerings. His focus on operational excellence, innovation, and customer partnerships has positioned Maravai for sustained leadership in the evolving life sciences landscape.